Zibotentan (** Generic name only (development discontinued) **)

Other Medications

EU Not submitted to EMA ES Not available 1 Clinical Trials

Description

Zibotentan is an experimental drug that was studied in combination with standard chemotherapy (FOLFIRI: irinotecan, fluorouracil, leucovorin) for metastatic colorectal cancer that had progressed after treatment with oxaliplatin-based chemotherapy. The goal of the clinical trial was to see if adding zibotentan to FOLFIRI would improve progression-free survival (the time before the cancer starts growing again) compared to FOLFIRI alone. The trial also aimed to assess the safety and feasibility of this treatment combination. Zibotentan was given orally for 14 days, followed by a period of zibotentan alone for patients whose cancer stabilized. The trial also collected samples to study potential biomarkers related to the drug's effect. Development of zibotentan has been discontinued.

Mechanism of Action

Zibotentan is an antagonist of the endothelin A receptor (ETAR). Endothelins are substances in the body that can cause blood vessels to narrow. By blocking the ETAR, zibotentan may affect blood vessel function, potentially impacting tumor growth and spread. The specific role of ETAR in colorectal cancer and the exact mechanism by which zibotentan might affect it are areas of ongoing research.

Side Effects

The trial aimed to determine the toxicity profile of the combination therapy (FOLFIRI + zibotentan). Specific side effects related to zibotentan in this context are not detailed in the provided information But side effects associated with FOLFIRI (irinotecan Fluorouracil Leucovorin) are common and can include diarrhea Nausea Vomiting Fatigue Low blood counts And mucositis (inflammation of the lining of the digestive tract). The specific side effects observed in the trial involving zibotentan are being evaluated.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT01205711 Phase 2
Archived
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer
United Kingdom

Quick Info

Brand Name** Generic name only (development discontinued) **
CategoryOther Medications
EU EMA StatusNot submitted to EMA
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
781 trials
Leucovorin
Other Medications
641 trials
Paclitaxel
Other Medications
54 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Trifluridine
Other Medications
48 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.